

IN THE CLAIMS:

Please amend the claims as follows:

02
Claim 1 (twice amended). A topically-applicable photodynamic medicament, the medicament comprising at least one halogenated xanthene as a photoactive component, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, and wherein said medicament is useful for treatment of diseases of human and animal tissue.

~~Cancel Claim 4.~~

13
Claim 5 (amended). The medicament of Claim 1 further comprising at least one chemical or biological targeting moiety coupled to said halogenated xanthene, wherein said targeting moiety is selected from the group consisting of deoxyribonucleic acids (DNA), ribonucleic acids (RNA), amino acids, proteins, antibodies, ligands, haptens, carbohydrate receptors, carbohydrate complexing agents, lipid receptors, lipid complexing agents, protein receptors, protein complexing agents, chelators, encapsulating vehicles, short-chain aliphatic hydrocarbons, long-chain aliphatic hydrocarbons, aromatic hydrocarbons, aldehydes, ketones, alcohols, esters, amides, amines, nitriles, azides, hydrophilic moieties and hydrophobic moieties.

~~Cancel Claim 6.~~

Claim 12 (twice amended). The medicament of Claim 1 wherein said medicament is activated using light having a wavelength of between approximately 500 nm and 600 nm.

D⁴
Claim 13 (twice amended). Use of a halogenated xanthene as a photoactive component in the preparation of a topical medicament for treatment of human and animal tissue using photodynamic therapy, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claim 17 (amended). Use of a halogenated xanthene comprising:

D⁵
topically administering a therapeutically effective amount of a halogenated xanthene to or proximate to human or animal tissue and photoactivating the halogenated xanthene present within or proximate to said tissue, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

D⁶
Claim 21 (amended). A pharmaceutical composition for topical administration comprising a halogenated xanthene for treatment using photodynamic therapy, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl

D⁴
Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Cancel Claim 24.

D⁷
Claim 25 (amended). The pharmaceutical composition of Claim 21 further comprising at least one chemical or biological targeting moiety coupled to said halogenated xanthene, wherein said targeting moiety is selected from the group consisting of deoxyribonucleic acids (DNA), ribonucleic acids (RNA), amino acids, proteins, antibodies, ligands, haptens, carbohydrate receptors, carbohydrate complexing agents, lipid receptors, lipid complexing agents, protein receptors, protein complexing agents, chelators, encapsulating vehicles, short-chain aliphatic hydrocarbons, long-chain aliphatic, aromatic hydrocarbons, aldehydes, ketones, alcohols, esters, amides, amines, nitriles, azides, hydrophilic moieties and hydrophobic moieties.

Cancel Claim 26.

D⁸
Claim 32 (twice amended). A method of treating diseased tissue comprising:
topically applying a medicament including at least one halogenated xanthene to or proximate to diseased human or animal tissue, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or

D⁸
Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein; and illuminating said human or animal tissue with light to photoactivate said halogenated xanthene present within or proximate to said tissue.

Claim 36 (twice amended). A topically-applicable medicament comprising at least one halogenated xanthene as a photoactive component, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, and, wherein such medicament is useful for photodynamic treatment of human and animal tissue.

D⁹
Claim 37 (twice amended). A topically-applicable medicament comprising at least one halogenated xanthene as a primary active component, wherein said halogenated xanthene includes at least one compound selected from the group consisting of Eosin Y; Ethyl Eosin; Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, and wherein such medicament is useful for photodynamic treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the